Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257865 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
A Phase 3 study of Bipolar I Disorder and Manic Episode, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
- 20
- Study locations
NCT03257865 is a Phase 3 study of Bipolar I Disorder and Manic Episode that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 333 participants, roughly in line with the 317-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT03257865, a Phase 3 study of Bipolar I Disorder and Manic Episode, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brexpiprazole
Study Locations (20)
California
- CiTrials - Bellflower
- CNS Research Science Inc. - Cerritos
- Apostle Clinical Trials - Long Beach
- CNRI-San Diego - San Diego
- Artemis Institute for Clinical Research - San Diego
- CiTrials - Santa Ana
- Collaborative Neuroscience Network, LLC - Torrance
- Shreenath Clinical Service - Yorba Linda
Florida
- Galiz Research - Hialeah
- Research Centers of America LLC - Hollywood
- Optimus U Corporation - Miami
- South Florida Research Phase I-IV - Miami Springs
- Meridien Research - Orlando
Arkansas
- Atria Clinical Research - Little Rock
- Woodland International Research Group, LLC - Little Rock
Illinois
- Uptown Research Institute LLC - Chicago
- Neuropsychiatric Research & Associates, LTD - Winfield
Georgia
- iResearch Atlanta, LLC - Decatur
Louisiana
- Louisiana Clinical Research - Shreveport
Missouri
- Arch Clinical Trials, LLC - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257865
The ClinicalTrials.gov registry entry for NCT03257865 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 317-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bipolar I Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03257865 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03257865 about?
NCT03257865 is a clinical study titled "A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder". To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
What is the current status of trial NCT03257865?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2017-09-19. Estimated completion is 2019-01-22.
What conditions does trial NCT03257865 study?
This clinical trial studies the following conditions: Bipolar I Disorder, Manic Episode.
What interventions are being tested in trial NCT03257865?
The interventions under investigation include: Placebo (DRUG), Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT03257865?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257865 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar I Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
COMPLETED · Phase 3
-
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
COMPLETED · Phase 3
-
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.